DBV Technologies (NASDAQ: DBVT) — Perfil da empresa, notícias e dados financeiros
DBV Technologies is a biopharmaceutical company focused on treatments for food allergies using innovative Viaskin technology.
DBV Technologies
DBV Technologies (EPA:DBV), (NASDAQ:DBVT) is a biopharmaceutical company focused on developing and commercializing treatments for food allergies, particularly peanut allergies in children, through its innovative Viaskin technology. This epicutaneous immunotherapy (EPIT) platform leverages a patch-based approach aiming to provide a non-invasive treatment option for patients. DBV Technologies is committed to improving the lives of those suffering from food allergies by advancing research and striving towards the commercial availability of their treatments. Operating with a strong commitment to safety, efficacy, and patient accessibility, their primary objective is to bring transformative therapies to the market, addressing a significant unmet need within the allergy therapeutic space.
Resumo
Operações
Produtos e/ou serviços de DBV Technologies
- Viaskin Patch, a novel immunotherapy platform aimed at treating food allergies through epicutaneous delivery.
- Viaskin Peanut, designed for children aged 4-11 with peanut allergies, seeking FDA approval.
- Product pipeline includes Viaskin Milk for milk allergy treatment and Viaskin Egg for egg allergy, both in early development stages.
- Collaborations with academic and industry partners to explore Viaskin's platform for other allergies.
- Research and development in novel diagnostic tools for food allergies.
- Expanding applications of the Viaskin platform to address other immune-related disorders beyond allergies.
equipe executiva do DBV Technologies
- Daniel TasséCEO & Director
- Virginie Simone Jeanine Verrechia BoucinhaChief Financial Officer
- Pharis MohideenChief Medical Officer
- Kevin P. MalobiskyChief Operations Officer
- Jonathan NeelyVP & Head of Investor Relations
- Michele F. RobertsonChief Legal Officer
- James BriggsChief Human Resources Officer
- Kevin TrappChief Commercial Officer
- Alan KerrSenior VP & Head of Global Regulatory Affairs
- Pascal WotlingChief External Manufacturing & Supply Chain Officer
Últimas notícias sobre a DBV Technologies
Principais indicadores financeiros
Resultados divulgados pela DBV Technologies, em USD.
- Cap. de mercado
- 669,3 mi
- Receita (TTM)
- 5 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -147,1 mi | -146,9 mi | |
| 2,6 mi | -120,5 mi | -113,7 mi | |
| 15,7 mi | -76,4 mi | -72,7 mi | |
| 4,8 mi | -96,6 mi | -96,3 mi |